Skin metastases from urothelial carcinoma of the bladder are uncommon, and there are few cases reported in literature. The present case report describes the results of a combination of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) administered as second-line chemotherapy in a cisplatin-resistant metastatic bladder cancer patient. The improvement in cutaneous lesions and pain reduction obtained prompt further exploration of the activity of this regimen in a second-line approach.
BerrutiA., GerbinoA., FaggiuoloR., RoveroE., DogliottiL.: Third-line chemotherapy with mitomycin C and lonidamine in advanced bladder cancer. Partial response in a patient with skin and lung metastases.Tumori,81: 39–41, 1995.
4.
NouiraY., KbaierI., AttyaouiF., HorchaniA.: Skin metastases of urothelial carcinoma of the bladder: a case report.Tunis Med,77: 233–235, 1999.
5.
SaxmanS.B., PropertK.J., EinhornL.H., CrawfordE.D., TannockI., RaghavanD., LoehrerP.J., TrumpD.: Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.J Clin Oncol,15: 2564–2569, 1997.
6.
von der MaaseH., HansenS.W., RobertsJ.T., DogliottiL., OliverT., MooreM.J., BodrogiI., AlbersP., KnuthA., LippertC.M., KerbratP., Sanchez RoviraP., WersallP., CleallS.P., RoychowdhuryD.F., TomlinI., Visseren-GrulC.M., ConteP.F.: Gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin and cisplatin (MVAC) chemotherapy in advanced or metastatic transitional cell carcinoma (TCC) of the urothelium: a large randomized, multicenter, multinational phase III study.J Clin Oncol,18: 3068–3077, 2000.
7.
LorussoV., RosatiG., CrucittaE., ManzioneL., PalmeriS., GebbiaV., MancarellaS., SobreroA., PezzellaG., CorneliaP., MangiameliA., MuciD., De LenaM.: Paclitaxel, gemcitabine and cisplatin versus gemcitabine-cisplatin in advanced transitional cell carcinoma of the urinary tract (ATCC). A phase II randomised study of the Southern Italy Cooperative Oncology Group (SICOG).Ann Oncol, 12 (Suppl 4): 37, 2001.
8.
SweeneyC.J., WilliamsS.D., FinchD.E., BihrleR., FosterR.S., CollinsM., FoxS., RothB.J.: A phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium.Cancer,86: 514–518, 1999.
9.
OttoT., BexA., KregeS., WalzP.H., RubbenH.: Paclitaxel-based second-line therapy for patients with advanced chemotherapy-resistant bladder carcinoma (Ml): a clinical phase II study.Cancer,80: 465–470, 1997.
10.
AloiF., SolaroliC., ParadisoM., FormiconiA.: Inflammatory type cutaneous metastasis of bladder neoplasm: erysipeloid carcinoma.Minerva Urol Nefrol,50: 205–208, 1998.
